全文获取类型
收费全文 | 343篇 |
免费 | 32篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 8篇 |
妇产科学 | 4篇 |
基础医学 | 98篇 |
口腔科学 | 1篇 |
临床医学 | 31篇 |
内科学 | 130篇 |
神经病学 | 3篇 |
特种医学 | 30篇 |
外科学 | 9篇 |
综合类 | 20篇 |
预防医学 | 6篇 |
药学 | 5篇 |
肿瘤学 | 29篇 |
出版年
2019年 | 4篇 |
2018年 | 5篇 |
2014年 | 13篇 |
2013年 | 6篇 |
2012年 | 10篇 |
2011年 | 11篇 |
2010年 | 8篇 |
2009年 | 6篇 |
2008年 | 7篇 |
2007年 | 19篇 |
2006年 | 7篇 |
2005年 | 7篇 |
2004年 | 10篇 |
2003年 | 6篇 |
2002年 | 13篇 |
2001年 | 12篇 |
2000年 | 9篇 |
1999年 | 16篇 |
1998年 | 9篇 |
1997年 | 13篇 |
1996年 | 5篇 |
1995年 | 9篇 |
1994年 | 13篇 |
1993年 | 11篇 |
1992年 | 9篇 |
1991年 | 7篇 |
1990年 | 5篇 |
1989年 | 8篇 |
1988年 | 3篇 |
1987年 | 8篇 |
1986年 | 5篇 |
1985年 | 6篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 5篇 |
1981年 | 5篇 |
1980年 | 5篇 |
1979年 | 5篇 |
1978年 | 7篇 |
1976年 | 6篇 |
1975年 | 5篇 |
1973年 | 5篇 |
1971年 | 2篇 |
1970年 | 2篇 |
1969年 | 4篇 |
1968年 | 4篇 |
1967年 | 4篇 |
1966年 | 7篇 |
1965年 | 3篇 |
1962年 | 3篇 |
排序方式: 共有375条查询结果,搜索用时 31 毫秒
1.
Steven G. E. Marsh Ekkehard D. Albert Walter F. Bodmer Ronald E. Bontrop Bo Dupont Henry A. Erlich Daniel E. Geraghty John A. Hansen Bernard Mach Wolfgang R. Mayr Peter Parham Effie W. Petersdorf Takehiko Sasazuki Geziena M. Th. Schreuder Jack L. Strominger Arne Svejgaard Paul I. Terasaki 《International journal of immunogenetics》2002,29(6):463-515
2.
3.
Genotype-phenotype correlation for nucleotide substitutions in the IgII- IgIII linker of FGFR2 总被引:6,自引:3,他引:3
4.
Not a choice, an obligation. 总被引:3,自引:0,他引:3
R G Petersdorf 《Academic medicine》1992,67(2):73-79
The author traces the gradual increase of educational opportunities for underrepresented minorities that began in the mid-1950s and indicates the role played by the Association of American Medical Colleges (AAMC) and individual medical schools in the 1960s and 1970s to increase minority enrollment in medical schools. Minority enrollment did grow dramatically for awhile, but since 1974 the nationwide percentage of minority students enrolling has remained about the same despite the rising percentage of minorities in the population (although some individual schools have recruited and graduated relatively large numbers of minority students). The author then emphasizes how crucial to the nation's future it is to reverse this trend and achieve equity of opportunity for minorities by enhancing their educational opportunities. He maintains that academic medical centers must become involved in identifying and assisting capable minority students well before they are potential applicants to medical school, thereby helping to enlarge the pool of academically qualified minority applicants rather than relying on more aggressive recruitment from the existing small applicant pool. Enlarging the minority applicant pool is the cornerstone of a new AAMC campaign nearly to double the number of underrepresented minority matriculants by the beginning of the next decade: Project 3000 by 2000. The short-term and long-term strategies of this campaign are described; it focuses on creating partnerships with high schools and undergraduate colleges and will be based in part on a variety of existing and successful efforts of this type being made by individual medical schools, private foundations, and the federal government.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
5.
Mickelson EM Petersdorf E Anasetti C Martin P Woolfrey A Hansen JA 《Human immunology》2000,61(2):92-100
Progress in hematopoietic cell transplantation has been greatly facilitated by our increasing knowledge of the HLA system, as well as by improved therapies for achieving sustained engraftment, preventing graft-versus-host disease, and protecting the patient from infection. Disparity for HLA genes can cause graft rejection and graft-versus-host disease and decrease survival in patients receiving grafts from both related and unrelated donors. The presence of patient alloantibodies against donor antigens demonstrated by a positive crossmatch is a strong risk factor for graft rejection. The availability of matched donors for patients lacking a genotypically HLA-matched sibling has been greatly improved by the establishment of international registries of HLA-typed volunteer donors. The development of accurate and reproducible high-resolution DNA-based typing methods has significantly improved the prospects for identifying unrelated donors who are well matched with the patient for HLA. The use of these methods to optimize donor selection will improve both donor identification and the success of unrelated donor transplants. 相似文献
6.
Evaluation of the mixed lymphocyte culture (MLC) assay as a method for selecting unrelated donors for marrow transplantation 总被引:2,自引:0,他引:2
E. M. Mickelson G. Longton C. Anasetti E. Petersdorf P. Martin L. A. Guthrie J. A. Hansen 《Tissue antigens》1996,47(1):27-36
Abstract: The utility of the MLC assay as a test of HLA-D region matching and predictor of graft-versus-host disease (GvHD) was evaluated in 435 patients receiving marrow grafts from unrelated donors. Donors and recipients were phenotyped for HLA-A, B and DR antigens by serology, tested in MLC, and retrospectively genotyped for DRB1, B3, B4, B5, DQB1 and DPB1 alleles by PCR/SSOP. Of the 244 HLA-A, B, DR-identical donor-recipient pairs with evaluable MLC and DRB1 typing results available, 208 were matched for HLA-A, B and DRB1, while 36 were matched for HLA-A and B and mismatched for a DRB1 allele. Donor anti-recipient relative responses (RR) in MLC, corresponding to the GvHD vector in marrow transplantation, ranged from 7.2 to 100%, with a median of 4.0%. A comparison of reactivity in MLC between pairs matched versus mismatched for DRB1 alleles showed a significant overlap in the distribution of RRs. Using optimally-defined RR cutoffs of 4 and 16%, no correlation between MLC results and risk of developing clinically significant grades III-IV GvHD (p=0.6 and 0.5, respectively) was found when the contribution of DRB1 mismatch was accounted for. Matching for DRB1 alleles, in contrast, was a better predictor of clinically significant GvHD, with DRB1-matched transplant recipients less likely to develop grades III-IV GvHD than DRB1-mismatched recipients (p=0.14). Among the 208 patients and donors matched for DRB1 alleles, the MLC, although reactive (RR > 4.0%) in 45% of cases, did not predict GvHD. Overall, these results underscore the limitations in using the MLC to predict DRB1 matching or risk of clinically significant GvHD among patients receiving unrelated marrow grafts. The availability of DRB1 allele matching by sequence-specific oligonucleotide probes (SSOP) or by direct sequencing provides a method for donor matching that is rapid, precise and superior to the MLC for predicting clinically relevant outcome. 相似文献
7.
Paul J Martin George B McDonald Jean E Sanders Claudio Anasetti Frederick R Appelbaum H Joachim Deeg Richard A Nash Effie W Petersdorf John A Hansen Rainer Storb 《Biology of blood and marrow transplantation》2004,10(5):320-327
The reported incidence of grades II to IV acute graft-versus-host disease (GVHD) after hematopoietic cell transplantation with HLA-identical sibling donors has increased considerably during the past 15 to 20 years at our center. The purpose of this study was to evaluate the potential reasons for this change. We reviewed organ stages and overall grades of GVHD for 2220 patients who received a first marrow or peripheral blood cell transplant from an HLA-identical sibling or an HLA-allele-matched unrelated donor with the use of a posttransplantation immunosuppressive regimen that included both methotrexate and cyclosporine between 1985 and 2001. The most striking change was an increased incidence of stage 1 gut involvement from 10% to 20% before 1992 to 50% to 60% since 1992, both with related and unrelated donors. This change increased the incidence of grade II GVHD with sibling donors, such that the overall incidence of grade II to IV GVHD is now 60% to 70%. Among patients with chronic myeloid leukemia in chronic phase, the increasingly frequent diagnosis of acute GVHD since 1992 has not been associated with decreased survival. A high diagnostic sensitivity and increased awareness that gut GVHD can occur without skin involvement account for the increased incidence of acute GVHD at our center. 相似文献
8.
L Ozzello CM De Rosa EW Blank K Cantell RL Ceriani DV Habif Sr 《Breast cancer research and treatment》1993,25(3):265-276
Summary An immunoconjugate composed of natural interferon (nIFN) bound in a noncleavable fashion to a monoclonal antibody (MoAb) recognizing a breast epithelial membrane mucin (Mc5) was used to treat xenografts of a human mammary carcinoma cell line (MCF-7) growing in nude mice. The immunoconjugate (nIFN/Mc5) was administered as 20 intralesional (i.l.) injections to 1 of 2 xenografts in each animal. It was found that nIFN/Mc5 produced a significant enhancement of the growth inhibitory actions of nIFN on the injected tumors. Further enhancement was obtained when nIFN or nIFN together with Mc5 (at a dose 10 times larger than that present in nIFN/Mc5) were added to the immunoconjugate. Biodistribution experiments showed that the uptake of125I-nIFN/Mc5 by the tumors was greater and its elimination slower than for125I-nIFN alone or conjugated to irrelevant mouse IgG1. In addition, the immunoconjugate up-regulated the antigenic expression of a breast epithelial membrane mucin by the carcinoma cells, an up-regulation which was not significantly different from that produced by nIFN alone. The contralateral noninjected tumors exposed to systemic levels of the immunoconjugate showed an enhancement of antitumor effects, but to a lesser extent than the injected tumors. These findings suggest that the enhancement of the growth inhibitory action of the immunoconjugate was related to the specific binding of Mc5 which targeted the IFN to the carcinoma cells and impeded its elimination. It is likely that the targeting was favored by the IFN-mediated up-regulation of antigenic expression by the carcinoma cells, thereby producing a cascade of interrelated effects. The results of this study point out the feasibility and potential usefulness of IFN treatment by means of immunoconjugates as well as the worth of pursuing and improving this form of therapy. 相似文献
9.
Informed consent, parental awareness, and reasons for participating in a randomised controlled study
M van Stuijvenberg MH Suur S de Vos GC Tjiang EW Steyerberg G Derksen-Lubsen HA Moll 《Archives of disease in childhood》1998,79(2):120-125
BACKGROUND: The informed consent procedure plays a central role in randomised controlled trials but has only been explored in a few studies on children. AIM: To assess the quality of the informed consent process in a paediatric setting. METHODS: A questionnaire was sent to parents who volunteered their child (230 children) for a randomised, double blind, placebo controlled trial of ibuprofen syrup to prevent recurrent febrile seizures. RESULTS: 181 (79%) parents responded. On average, 73% of parents were aware of the major study characteristics. A few had difficulty understanding the information provided. Major factors in parents granting approval were the contribution to clinical science (51%) and benefit to the child (32%). Sociodemographic status did not influence initial participation but west European origin of the father was associated with willingness to participate in future trials. 89% of participants felt positive about the informed consent procedure; however, 25% stated that they felt obliged to participate. Although their reasons for granting approval and their evaluation of the informed consent procedure did not differ, relatively more were hesitant about participating in future. Parents appreciated the investigator being on call 24 hours a day (38%) and the extra medical care and information provided (37%) as advantages of participation. Disadvantages were mainly the time consuming aspects and the work involved (23%). CONCLUSIONS: Parents' understanding of trial characteristics might be improved by designing less difficult informed consent forms and by the investigator giving extra attention and information to non-west European parents. Adequate measures should be taken to avoid parents feeling obliged to participate, rather than giving true informed consent. 相似文献
10.
HLA matching in allogeneic stem cell transplantation 总被引:6,自引:0,他引:6
Petersdorf EW 《Current opinion in hematology》2004,11(6):386-391
PURPOSE OF REVIEW: The success of unrelated hematopoietic cell transplantation (HCT) is influenced by the degree of HLA compatibility between the donor and patient. The goal of this review is to summarize new findings in the field of immunogenetics and HCT from unrelated donors using myeloablative conditioning regimens. RECENT FINDINGS: Molecular typing methods can discriminate unique alleles encoded by HLA class I and II genes. Incompatibility of donor-recipient HLA alleles increases posttransplant complications including graft rejection, acute and chronic graft-versus-host disease, and mortality. These posttransplant risks increase with increasing numbers of HLA mismatches. The identification of permissible HLA mismatches may be aided by the use of functional assays. Nongenetic factors, including the stage of disease at the time of transplantation, may influence the effect of HLA mismatching on survival. SUMMARY: HLA alleles are functionally relevant. Unrelated HCT can be optimized by comprehensive and precise donor-recipient allele matching. For patients with high-risk diseases who lack matched donors, use of donors with a single HLA mismatch may permit early treatment before disease progression. 相似文献